<unk> , or<unk> , is the name of a modified polio virus that has recently shown promise for treating cancer. It is the focus of clinical trials being conducted at Duke University.<unk>  consists of a genetically modified nonpathogenic version of the oral poliovirus Sabin type 1. The internal ribosome entry site (IRES) on the poliovirus was replaced with the IRES from human rhinovirus type 2 (HRV2), to avoid neurovirulence. Once administered, the virus enters and begins replicating within cells that express CD155/Necl5, which is an onco-fetal cell adhesion molecule that is common across solid tumors. A website at Duke University describes many of properties of<unk> , and historical background about using viruses to oppose cancer. According to that website, The potential value of<unk>  was the focus of a 2015 story on 60 Minutes. In May 2016, the US FDA granted it Breakthrough therapy designation for Glioblastoma.
PVSRIPO
DRACO
OHVIRA
CORE-OM
SCoRS
ICECI
TOLAC
PREPARE